Skip to content
Triangle logo TriangleGet started
← Study library

NCT03126630 · REGISTRY CONDITION SEARCH

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-04-01

This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma. Anetumab ravtansine is a monoclonal antibody, called anetumab, linked to a chemotherapy drug, called ravtansine. Anetumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as mesothelin receptors, and delivers ravtansine to kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and anetumab ravtansine may work better in treating patients with mesothelin-positive pleural mesothelioma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase 2 Confirmed Tumor Response Rate (Phase II)

→

outcome · POSTED

Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab

→

outcome · POSTED

Phase 2 Duration of Response

→

outcome · POSTED

Phase 2 Overall Survival

→

outcome · POSTED

Phase 2 Progression Free Survival

→

outcome · NOT POSTED

Pharmacokinetics of Anetumab Ravtansine

→

outcome · NOT POSTED

Change in Megakaryocyte Potentiating Factor Levels Assessed in Tumor

→

outcome · NOT POSTED

Mononuclear Phagocyte System -FcgammaRs and Chemokine Mediators of Mononuclear Phagocyte System

→

outcome · NOT POSTED

Incidence of Adverse Events

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * PRE-REGISTRATION * Patients must have histologically or cytologically confirmed malignant pleural mesothelioma * Patient is willing to submit a tissue sample to test for expression of mesothelin * Note: Tissue sample for mesothelin assay may have been collected prior to, during or after receipt of the frontline chemotherapy; patients will not be required to submit another tissue sample after receipt of the chemotherapy * Patients must have received platinum based chemotherapy * REGISTRATION * For phase 2 only: * Patient has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for non-pleural disease or modified RECIST 1.1 (mRECIST) for pleural disease * Note: For pleural disease, this is defined as at least one lesion that can be accurately measured perpendicular to the chest wall or mediastinum that is \>= 10 mm (\>= 1 cm); for extra pleural disease, measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 10 mm (\>= 1 cm) for non-nodal lesions and \>= 15 mm (\>= 1.5 cm) for nodal lesions with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam as per RECIST 1.1 * Tissue submitted for testing at pre-registration shows moderate or stronger mesothelin expression in \>= 30% of the tumor cells * For phase 1 and 2: * Patients must have received platinum-based therapy with or without bevacizumab * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (Karnofsky \>= 70%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal (ULN) * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * International normalized ratio (INR) or prothrombin time (PT) =\< 1.5 x ULN AND partial thromboplastin time (PTT) or activated PTT (aPTT) =\< 1.5 x ULN, unless patient is on stable dose of anti-coagulation therapy in which case patients will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion * Negative serum pregnancy test for females of child bearing potential * Note: Females are considered to not be of child bearing potential if any of the following apply: * Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women \< 45 years of age, a high follicle stimulating hormone \[FSH\] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); * Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; * Has a congenital or acquired condition that prevents childbearing * Patient agrees to use one of the following acceptable methods of contraception prior to study entry, during study participation, and for at least six months after receiving the last dose of study treatment: * Acceptable methods of contraception are: * Single method (1 of the following is acceptable): * Abstinence, if consistently employed as the patient's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and Institutional Review Boards (IRBs) * Intrauterine device (IUD) * Vasectomy of a female patient's male partner * Contraceptive rod implanted into the skin * Combination method (requires use of 2 of the following): * Diaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide) * Cervical cap with spermicide (nulliparous women only) * Contraceptive sponge (nulliparous women only) * Male condom or female condom (cannot be used together) * Hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or progestin-only pill), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection * Ability to understand and the willingness to sign a written informed consent document, unless patient is of impaired decision making capacity in which case patient may be eligible if they have a legal authorized representative or caretaker available Exclusion Criteria: * Patients who have received any monoclonal antibody therapy within 4 weeks prior to entering the study * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) * Note: Patients with =\< grade 2 neuropathy or =\< grade 2 alopecia are an exception to this criterion and may qualify for the study * Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy * Patients who are receiving any other investigational agents * Patients with known brain metastases with progressive neurologic dysfunction, requirement of steroids and lack of improvement on head imaging obtained prior to consent to this clinical trial should be excluded because of their poor prognosis and because they would confound the evaluation of neurologic and other adverse events * Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment * Note: Patients with carcinomatosis meningitis should also be excluded * History of allergic reactions attributed to compounds of similar chemical or biologic composition to anetumab ravtansine or pembrolizumab * Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4, including herbal preparation containing CYP3A4 inducers (e.g., St. John's Wort), grapefruit and grapefruit juice (CYP3A4 inhibitor), within 2 weeks before the start of study treatment * Patients are prohibited from receiving the following therapies during the screening and treatment phases (including retreatment for post-complete response relapse) of this trial: * Antineoplastic systemic chemotherapy or biological therapy * Immunotherapy not specified in this protocol * Chemotherapy not specified in this protocol * Investigational agents other than anetumab ravtansine and pembrolizumab * Radiation therapy (Note: Radiation therapy to a symptomatic solitary lesion or to the brain may be considered on an exceptional case by case basis after consultation with Cancer Therapy Evaluation Program (CTEP); the patient must have clear measurable disease outside the radiated field; administration of palliative radiation therapy will be considered clinical progression for the purposes of determining progression free survival \[PFS\]) * Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Chalmette-Guerin (BCG), and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed * Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology; the use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI) and CTEP * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Women who are pregnant or breastfeeding. * Note: Pregnant women are excluded from this study because anetumab ravtansine and pembrolizumab are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with anetumab ravtansine and pembrolizumab, breastfeeding should be discontinued if the mother is treated with anetumab ravtansine or pembrolizumab * Human immunodeficiency virus (HIV)-positive patients who do not meet all of the following and/or are on HIV medications considered to be strong inhibitors or inducers of CYP3A4: * Undetectable HIV viral load by standard clinical assay within 6 months of registration * Willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy * No acquired immunodeficiency syndrome (AIDS)-defining events other within the past 12 months * Near normal life expectancy if not for the presence of the cancer * Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid \[RNA\] \[qualitative\] is detected) infection * Note: No testing for hepatitis B and hepatitis C is required unless mandated by local health authority * Patients who are known to have a history of or a finding of corneal epitheliopathy at pre-study are excluded because anetumab ravtansine may worsen this condition and reduce vision * Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer * Receipt of transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor \[G-CSF\], granulocyte macrophage colony-stimulating factor \[GM-CSF\], or recombinant erythropoietin) within 4 weeks prior to study treatment * Patient with active interstitial lung disease (ILD)/pneumonitis or a prior history of ILD/pneumonitis requiring treatment with steroids * Patient has received prior treatment with PD-1, PD-L1 or PD-L2 inhibitor
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
    intervention Names
    1. Other: Laboratory Biomarker Analysis
    2. Biological: Pembrolizumab
    3. Other: Pharmacological Study
    label
    Group I (pembrolizumab)
    type
    ACTIVE_COMPARATOR
  2. description
    Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: Anetumab Ravtansine
    2. Other: Laboratory Biomarker Analysis
    3. Biological: Pembrolizumab
    4. Other: Pharmacological Study
    label
    Group II (anetumab ravtansine, pembrolizumab)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Group II (anetumab ravtansine, pembrolizumab)
    description
    Given IV
    name
    Anetumab Ravtansine
    other Names
    1. BAY 94-9343
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Group I (pembrolizumab)
    2. Group II (anetumab ravtansine, pembrolizumab)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  3. arm Group Labels
    1. Group I (pembrolizumab)
    2. Group II (anetumab ravtansine, pembrolizumab)
    description
    Given IV
    name
    Pembrolizumab
    other Names
    1. BCD-201
    2. GME 751
    3. GME751
    4. Keytruda
    5. Lambrolizumab
    6. MK 3475
    7. MK-3475
    8. MK3475
    9. Pembrolizumab Biosimilar BCD-201
    10. Pembrolizumab Biosimilar GME751
    11. Pembrolizumab Biosimilar QL2107
    12. Pembrolizumab Biosimilar RPH-075
    type
    BIOLOGICAL
  4. arm Group Labels
    1. Group I (pembrolizumab)
    2. Group II (anetumab ravtansine, pembrolizumab)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
CROSSOVER
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
49
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1 criteria. The proportion of successes will be estimated in each group by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated in each arm. Comparison of confirmed response rates between the two treatment groups will be performed using a one-sided z-test with pooled variance at significance level 0.10. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
    measure
    Phase 2 Confirmed Tumor Response Rate (Phase II)
    time Frame
    Up to 2 years
  2. description
    All patients that have received any amount of the combination anetumab ravtansine and pembrolizumab will be evaluable for toxicity. Please note this is different from the definition of evaluable for dose-limiting toxicity (DLT) where patients who cannot complete the planned dose due to reasons other than toxicity will be replaced.
    measure
    Phase I - Recommended Phase 2 Dose of Ametumab Ravtansine With Combination of Pembrolizumab
    time Frame
    Up to 2 years
secondary Outcomes
  1. description
    Will be defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria. Will be estimated using the method of Kaplan-Meier. The comparison of duration of response between two treatment arms will be based on the log-rank test. This calculation will start with the date of start of treatment.
    measure
    Phase 2 Duration of Response
    time Frame
    Up to 2 years
  2. description
    Will be estimated using the method of Kaplan-Meier. The comparison of overall survival in event of death between two treatment arms will be based on the log-rank test.
    measure
    Phase 2 Overall Survival
    time Frame
    From the start of treatment to death due to any cause, assessed up to 2 years
  3. description
    Will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
    measure
    Phase 2 Progression Free Survival
    time Frame
    From the start of treatment to the earliest date of documentation of disease progression or death due to any cause, assessed up to 2 years
  4. description
    Will be largely descriptive. Changes over time will be plotted and assessed for each patient.
    measure
    Pharmacokinetics of Anetumab Ravtansine
    time Frame
    Days 1 and 3 of courses 1 and 8
  5. description
    Relative changes in biomarker levels will be compared by best overall response groups using the non-parametric Wilcoxon rank-sum test. Also, the associations between changes in megakaryocyte potentiating factor levels and ordered response categories (i.e. complete response-partial response-stable disease-progressive disease) will be assessed with the Jonckheere-Terpstra test for trend.
    measure
    Change in Megakaryocyte Potentiating Factor Levels Assessed in Tumor
    time Frame
    Baseline up to 2 years
  6. description
    The mean equivalent soluble fluorophore and antibody bound to cell (ABC) will be determined for each specimen. Linear regression will be used to explore the linear relationship between the continuous values of these mononuclear phagocyte system-FcgammaRs probes and anetumab ravtansine levels. The concentrations of CCL2 and CCL5 will be determined for each specimen. Linear regression will be used to explore the linear relationship between the continuous values of these chemokines and anetumab ravtansine levels.
    measure
    Mononuclear Phagocyte System -FcgammaRs and Chemokine Mediators of Mononuclear Phagocyte System
    time Frame
    Up to 2 years
  7. description
    To explore the symptomatic adverse events (AE) for tolerability of each treatment group using Patient Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE).
    measure
    Incidence of Adverse Events
    time Frame
    Up to 2 years
Full study description
brief Summary
This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma. Anetumab ravtansine is a monoclonal antibody, called anetumab, linked to a chemotherapy drug, called ravtansine. Anetumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as mesothelin receptors, and delivers ravtansine to kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and anetumab ravtansine may work better in treating patients with mesothelin-positive pleural mesothelioma.
detailed Description
PRIMARY OBJECTIVES: I. Determine the dose of anetumab ravtansine that is safe in combination with pembrolizumab to be used in the randomized phase 2 study. (Phase I safety lead-in) II. Determine if the overall response rate of the combination of anetumab ravtansine and pembrolizumab is superior to pembrolizumab alone. (Phase II) SECONDARY OBJECTIVES: I. To determine the progression free survival of anetumab ravtansine and pembrolizumab compared to pembrolizumab alone. II. To evaluate the pharmacodynamic effects of anetumab ravtansine and pembrolizumab on soluble megakaryocyte potentiating factor (MPF). III. To evaluate the pharmacokinetics of anetumab ravtansine and pembrolizumab. IV. To evaluate mononuclear phagocyte system (MPS) function, FcgammaRs, hormone and chemokine mediators as methods to evaluate factors affecting the pharmacokinetics and pharmacodynamics of these agents. V. To determine the incidence of antibodies directed against anetumab ravtansine. CORRELATIVE STUDY OBJECTIVES: I. To determine whether elevations in Bim in tumor-reactive T cells (TTR) predict responses to treatment and whether its detection is dynamic with treatment. II. To determine whether soluble PD-L1 predicts responses to treatment and whether its detection is dynamic with treatment. III. To evaluate PD-L1 expression in archival tissue as a predictive marker of response to pembrolizumab-based therapy. IV. To explore the symptomatic adverse events (AE) for tolerability of each treatment group using Patient Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE). OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II. GROUP II: Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 12 months.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-174873e9a18dd7b70070
      requested nct id
      NCT03126630
      primary nct id
      NCT03126630
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      payload sha256
      2616ce0da335cee2e9ed3792bae64bf419c92ce996fadeab066b680fc72b0974
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-174873e9a18dd7b70070
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03126630
      occurrences
      1. context exact
        NCT03126630
        end
        11
        exact text
        NCT03126630
        start
        0
      offset unit
      unicode_code_points
      query cond
      Malignant Mesothelioma
      query disease state id
      ds-malignant-mesothelioma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      source json pointer
      /studies/54/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      61447c77050831a19f602e0d5a869cb3a8b771612a1b81ba2781b089bf0e11aa

    Preserved source evidence · Not medical advice